Lenalidomide Monotherapy in R/R DLBCL
NCT04150328 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 490
Last updated 2022-08-24
Summary
This observational study is designed to characterise the effectiveness of lenalidomide monotherapy in the treatment of R/R DLBCL and to compare the results with the efficacy outcomes of a tafasitamab-lenalidomide combination therapy in the clinical trial MOR208C203 (L-MIND)
Conditions
Sponsors & Collaborators
-
MorphoSys AG
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-04-12
- Primary Completion
- 2019-08-25
- Completion
- 2020-08-25
Countries
- United States
- France
- Italy
- Spain
Study Locations
More Related Trials
-
Lenalidomide Plus Rituximab (R) in Non Follicular NHL
NCT01830478 ·Status: UNKNOWN ·Phase: PHASE2
-
Lenalidomide and R-CHOP in B-cell Lymphoma
NCT00901615 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT05552937 ·Status: RECRUITING ·Phase: PHASE2
-
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
NCT07240194 ·Status: RECRUITING ·Phase: PHASE2
-
Lenalidomide Based Immunotherapy in the Treatment of DLBCL
NCT03715296 ·Status: UNKNOWN
-
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
NCT05429268 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
NCT01185262 ·Status: COMPLETED ·Phase: PHASE1
-
Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma
NCT01556035 ·Status: COMPLETED ·Phase: PHASE2
-
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT02142049 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
NCT06651853 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065 ·Status: RECRUITING ·Phase: PHASE2
-
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
NCT06151080 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma
NCT03031483 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma
NCT01766583 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma
NCT02340936 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
NCT06299553 ·Status: RECRUITING
-
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
NCT05222555 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
NCT05923879 ·Status: UNKNOWN
-
Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas
NCT01788189 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
NCT04432402 ·Status: UNKNOWN ·Phase: NA
-
Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma
NCT04544059 ·Status: UNKNOWN ·Phase: PHASE2
-
Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL
NCT03367143 ·Status: UNKNOWN ·Phase: PHASE2
-
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
NCT02281279 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
NCT02128061 ·Status: COMPLETED ·Phase: PHASE3